{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T01:21:17Z","timestamp":1776216077711,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Foundation of Clinical Research Center of Shanghai University of Medicine & Health Sciences","award":["20MC2020004"],"award-info":[{"award-number":["20MC2020004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Screening of mRNAs and lncRNAs associated with prognosis and immunity of lung adenocarcinoma (LUAD) and used to construct a prognostic risk scoring model (PRS-model) for LUAD. To analyze the differences in tumor immune microenvironment between distinct risk groups of LUAD based on the model classification. The CMap database was also used to screen potential therapeutic compounds for LUAD based on the differential genes between distinct risk groups. he data from the Cancer Genome Atlas (TCGA) database. We divided the transcriptome data into a mRNA subset and a lncRNA subset, and use multiple methods to extract mRNAs and lncRNAs associated with immunity and prognosis. We further integrated the mRNA and lncRNA subsets and the corresponding clinical information, randomly divided them into training and test set according to the ratio of 5:5. Then, we performed the Cox risk proportional analysis and cross-validation on the training set to construct a LUAD risk scoring model. Based on the risk scoring model, patients were divided into distinct risk group. Moreover, we evaluate the prognostic performance of the model from the aspects of Area Under Curve (AUC) analysis, survival difference analysis, and independent prognostic analysis. We analyzed the differences in the expression of immune cells between the distinct risk groups, and also discuss the connection between immune cells and patient survival. Finally, we screened the potential therapeutic compounds of LUAD in the Connectivity Map (CMap) database based on differential gene expression profiles, and verified the compound activity by cytostatic assays. We extracted 26 mRNAs and 74 lncRNAs related to prognosis and immunity by using different screening methods. Two mRNAs (i.e., KLRC3 and RAET1E) and two lncRNAs (i.e., AL590226.1 and LINC00941) and their risk coefficients were finally used to construct the PRS-model. The risk score positions of the training and test set were 1.01056590 and 1.00925190, respectively. The expression of mRNAs involved in model construction differed significantly between the distinct risk population. The one-year ROC areas on the training and test sets were 0.735 and 0.681. There was a significant difference in the survival rate of the two groups of patients. The PRS-model had independent predictive capabilities in both training and test sets. Among them, in the group with low expression of M1 macrophages and resting NK cells, LUAD patients survived longer. In contrast, the monocyte expression up-regulated group survived longer. In the CMap drug screening, three LUAD therapeutic compounds, such as resveratrol, methotrexate, and phenoxybenzamine, scored the highest. In addition, these compounds had significant inhibitory effects on the LUAD A549 cell lines. The LUAD risk score model constructed using the expression of KLRC3, RAET1E, AL590226.1, LINC00941 and their risk coefficients had a good independent prognostic power. The optimal LUAD therapeutic compounds screened in the CMap database: resveratrol, methotrexate and phenoxybenzamine, all showed significant inhibitory effects on LUAD A549 cell lines.<\/jats:p>","DOI":"10.1038\/s41598-022-11052-8","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T12:03:54Z","timestamp":1651579434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunoprognostic model of lung adenocarcinoma and screening of sensitive drugs"],"prefix":"10.1038","volume":"12","author":[{"given":"Pengchen","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianguo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zezhou","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"11052_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. Ca Cancer J. Clin. 69, 7\u201334 (2019).","journal-title":"Ca Cancer J. Clin."},{"key":"11052_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2015.9","volume":"1","author":"C Gridelli","year":"2015","unstructured":"Gridelli, C. et al. Non-small-cell lung cancer. Nat. Rev. Dis. Primers 1, 1\u201316 (2015).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"11052_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121323","volume":"10","author":"R Meza","year":"2015","unstructured":"Meza, R., Meernik, C., Jeon, J. & Cote, M. L. Lung cancer incidence trends by gender, race and histology in the united states, 1973\u20132010. PloS One 10, e0121323 (2015).","journal-title":"PloS One"},{"key":"11052_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3322\/caac.21609","volume":"70","author":"F Bray","year":"2020","unstructured":"Bray, F. et al. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries (vol 68, pg 394, 2018). Ca Cancer J. Clin. 70, 313\u2013313 (2020).","journal-title":"Ca Cancer J. Clin."},{"key":"11052_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00595-017-1497-7","volume":"48","author":"M Saito","year":"2018","unstructured":"Saito, M., Suzuki, H., Kono, K., Takenoshita, S. & Kohno, T. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surg. Today 48, 1\u20138 (2018).","journal-title":"Surg. Today"},{"key":"11052_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-2600(13)70009-2","volume":"1","author":"GM Stella","year":"2013","unstructured":"Stella, G. M., Luisetti, M., Pozzi, E. & Comoglio, P. M. Oncogenes in non-small-cell lung cancer: Emerging connections and novel therapeutic dynamics. Lancet Respir. Med. 1, 251\u2013261 (2013).","journal-title":"Lancet Respir. Med."},{"key":"11052_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.3934\/mbe.2020038","volume":"17","author":"G Sun","year":"2020","unstructured":"Sun, G. & Zhao, T. Lung adenocarcinoma pathology stages related gene identification. Math. Biosci. Eng. 17, 737\u2013746 (2020).","journal-title":"Math. Biosci. Eng."},{"key":"11052_CR8","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1158\/0008-5472.CAN-16-2634","volume":"77","author":"A Bhan","year":"2017","unstructured":"Bhan, A., Soleimani, M. & Mandal, S. S. Long noncoding rna and cancer: A new paradigm. Cancer Res. 77, 3965\u20133981 (2017).","journal-title":"Cancer Res."},{"key":"11052_CR9","first-page":"1","volume":"8","author":"J Zhou","year":"2018","unstructured":"Zhou, J. et\u00a0al. Long noncoding rna casc9. 5 promotes the proliferation and metastasis of lung adenocarcinoma. Sci. Rep.  8, 1\u201311 (2018).","journal-title":"Sci. Rep."},{"key":"11052_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.path.2019.11.002","volume":"13","author":"R Ruiz-Cordero","year":"2020","unstructured":"Ruiz-Cordero, R. & Devine, W. P. Targeted therapy and checkpoint immunotherapy in lung cancer. Surg. Pathol. Clin. 13, 17\u201333 (2020).","journal-title":"Surg. Pathol. Clin."},{"key":"11052_CR11","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.jtho.2020.08.020","volume":"15","author":"J Duan","year":"2020","unstructured":"Duan, J. et al. Refined stratification based on baseline concomitant mutations and longitudinal circulating tumor dna monitoring in advanced egfr-mutant lung adenocarcinoma under gefitinib treatment. J. Thorac. Oncol. 15, 1857\u20131870 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"11052_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cell.2020.05.043","volume":"182","author":"J-Y Xu","year":"2020","unstructured":"Xu, J.-Y. et al. Integrative proteomic characterization of human lung adenocarcinoma. Cell 182, 245\u2013261 (2020).","journal-title":"Cell"},{"key":"11052_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.canlet.2017.02.016","volume":"393","author":"Y Li","year":"2017","unstructured":"Li, Y. et al. Prognostic alternative mrna splicing signature in non-small cell lung cancer. Cancer Lett. 393, 40\u201351 (2017).","journal-title":"Cancer Lett."},{"key":"11052_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.lfs.2018.10.067","volume":"215","author":"Z Kaishang","year":"2018","unstructured":"Kaishang, Z. et al. Elevated expression of twinfilin-1 is correlated with inferior prognosis of lung adenocarcinoma. Life Sci. 215, 159\u2013169 (2018).","journal-title":"Life Sci."},{"key":"11052_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-10366-2","volume":"7","author":"J Chiou","year":"2017","unstructured":"Chiou, J. et al. Decrease of fstl1-bmp4-smad signaling predicts poor prognosis in lung adenocarcinoma but not in squamous cell carcinoma. Sci. Rep. 7, 1\u201311 (2017).","journal-title":"Sci. Rep."},{"key":"11052_CR16","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1080\/15384101.2019.1578146","volume":"18","author":"C Liu","year":"2019","unstructured":"Liu, C. et al. Identification of a novel glycolysis-related gene signature that can predict the survival of patients with lung adenocarcinoma. Cell Cycle 18, 568\u2013579 (2019).","journal-title":"Cell Cycle"},{"key":"11052_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07235-z","volume":"20","author":"H Jiang","year":"2020","unstructured":"Jiang, H., Xu, S. & Chen, C. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma. BMC Cancer 20, 1\u201311 (2020).","journal-title":"BMC Cancer"},{"key":"11052_CR18","unstructured":"TCGA. The cancer genome atlas (tcga) database. Website (2021). https:\/\/www.cancer.gov\/tcga."},{"key":"11052_CR19","unstructured":"Zhang, K. & Hong, W. Cancer genome atlas pan-cancer analysis project. Zhongguo Fei Ai Za Zhi 18 (2015)."},{"key":"11052_CR20","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb, J. The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929\u20131935 (2006).","journal-title":"Science"},{"key":"11052_CR21","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1093\/bib\/bbz129","volume":"21","author":"K Lin","year":"2020","unstructured":"Lin, K. et al. A comprehensive evaluation of connectivity methods for 1000 data. Brief Bioinform. 21, 2194\u20132205 (2020).","journal-title":"Brief Bioinform."},{"key":"11052_CR22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2337\/db20-0580","volume":"70","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. Connectivity mapping identifies bi-2536 as a potential drug to treat diabetic kidney disease. Diabetes 70, 589\u2013602 (2021).","journal-title":"Diabetes"},{"key":"11052_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2018.15","volume":"5","author":"S Bhattacharya","year":"2018","unstructured":"Bhattacharya, S. et al. Immport, toward repurposing of open access immunological assay data for translational and clinical research. Sci. Data 5, 180015 (2018).","journal-title":"Sci. Data"},{"key":"11052_CR24","unstructured":"Li, Z., Mao, K., Ding, B. & Xue, Q. Integrative analysis of multi-omics data identified klrc3 as key nodes in a gene regulatory network related to immune phenotypes in lung adenocarcinoma. Preprints."},{"key":"11052_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-957","volume":"14","author":"H Cho","year":"2014","unstructured":"Cho, H. et al. Mica\/b and ulbp1 nkg2d ligands are independent predictors of good prognosis in cervical cancer. BMC Cancer 14, 1\u201311 (2014).","journal-title":"BMC Cancer"},{"key":"11052_CR26","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3389\/fcell.2021.657667","volume":"9","author":"W Geng","year":"2021","unstructured":"Geng, W. et al. Identification of the prognostic significance of somatic mutation-derived lncrna signatures of genomic instability in lung adenocarcinoma. Front. Cell Dev. Biol. 9, 736 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"11052_CR27","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/ijc.31865","volume":"144","author":"L Wang","year":"2019","unstructured":"Wang, L. et al. Systematic identification of lincrna-based prognostic biomarkers by integrating lincrna expression and copy number variation in lung adenocarcinoma. Int. J. Cancer 144, 1723\u20131734 (2019).","journal-title":"Int. J. Cancer"},{"key":"11052_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-10-112","volume":"10","author":"J Ma","year":"2010","unstructured":"Ma, J. et al. The m1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 10, 1\u20139 (2010).","journal-title":"BMC Cancer"},{"key":"11052_CR29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nri2073","volume":"7","author":"H-G Ljunggren","year":"2007","unstructured":"Ljunggren, H.-G. & Malmberg, K.-J. Prospects for the use of nk cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7, 329\u2013339 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"11052_CR30","doi-asserted-by":"publisher","first-page":"946","DOI":"10.3390\/nu11050946","volume":"11","author":"L Malaguarnera","year":"2019","unstructured":"Malaguarnera, L. Influence of resveratrol on the immune response. Nutrients 11, 946 (2019).","journal-title":"Nutrients"},{"key":"11052_CR31","first-page":"925","volume":"57","author":"Y Fan","year":"2020","unstructured":"Fan, Y. et al. Resveratrol modulates the apoptosis and autophagic death of human lung adenocarcinoma a549 cells via a p53-dependent pathway: Integrated bioinformatics analysis and experimental validation. Int. J. Oncol. 57, 925\u2013938 (2020).","journal-title":"Int. J. Oncol."},{"key":"11052_CR32","doi-asserted-by":"publisher","first-page":"eaat5690","DOI":"10.1126\/scitranslmed.aat5690","volume":"11","author":"M Guo","year":"2020","unstructured":"Guo, M. et\u00a0al. Autologous tumor cell\u2013derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion. Sci. Transl. Med. 11, eaat5690 (2019).","journal-title":"Sci. Transl. Med."},{"key":"11052_CR33","unstructured":"Yoham, A.\u00a0L. & Casadesus, D. Phenoxybenzamine. StatPearls [Internet] (2021)."},{"key":"11052_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198514","volume":"13","author":"MA Inchiosa Jr","year":"2018","unstructured":"Inchiosa, M. A. Jr. Anti-tumor activity of phenoxybenzamine and its inhibition of histone deacetylases. PloS One 13, e0198514 (2018).","journal-title":"PloS One"},{"key":"11052_CR35","unstructured":"Pubchem. The pubchem database. Website (2021). https:\/\/pubchem.ncbi.nlm.nih.gov."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11052-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11052-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11052-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T02:17:11Z","timestamp":1669342631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11052-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["11052"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-11052-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"assertion":[{"value":"4 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7162"}}